<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="pop_total">0</item><item key="species">human</item><item key="factors"><item><item key="GSM929667"><item key="GESTATIONAL AGE">18.0</item></item></item><item><item key="GSM929668"><item key="GESTATIONAL AGE">17.1</item></item></item><item><item key="GSM929669"><item key="GESTATIONAL AGE">17.3</item></item></item><item><item key="GSM929670"><item key="GESTATIONAL AGE">18.8</item></item></item></item><item key="id">4486</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="platform">4</item><item key="summary_wrapped">Data on the temporal dynamics of human placental gene expression is scarce. We have completed the first whole-genome profiling of human...</item><item key="geo_gse_id">E-GEOD-37901</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">1</item><item key="sample_count">4</item><item key="tags"><item>central</item><item>disease</item><item>genome</item><item>gestational diabetes</item><item>median</item><item>placenta</item><item>preeclampsia</item><item>protein</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">mid-gestational-gene-expression-profile-in-placent</item><item key="geo_id_plat">E-GEOD-37901_A-AFFY-44</item><item key="name">Mid-gestational gene expression profile in placenta and link to pregnancy complications</item><item key="created">Sep.19, 2014</item><item key="summary">Data on the temporal dynamics of human placental gene expression is scarce. We have completed the first whole-genome profiling of human placental gene expression dynamics (GeneChips, Affymetrix&#174;) from early to mid- gestation (10 samples; gestational weeks 5 to 18) and report 154 genes with considerable change in transcript levels (FDR P&lt;0.1). Functional enrichment analysis revealed &gt;200 GO categories that are statistically over-represented among 105 genes with dynamically increasing transcript levels. Analysis in an extended sample (n=43; gestational weeks 5 to 41) conformed a highly significant (FDR P&lt;0.05) expressional peak in mid-gestation placenta for ten genes: BMP5, CCNG2, CDH11, FST, GATM, GPR183, ITGBL1, PLAGL1, SLC16A10, STC1. A central hypothesis of our study states that the aberrant expression of genes characteristic to mid-gestation placenta may contribute to affected fetal growth, maternal preeclampsia (PE) or gestational diabetes (GD). The gene STC1 coding for Stanniocalcin 1 (STC1) was identified with a sharp placental expressional peak in mid-gestation, increased mRNA levels at term and significantly elevated STC1 protein levels in post-partum maternal plasma in all pregnancy complications. The highest STC1 levels were identified in women, who developed simultaneously PE and delivered an SGA baby (median 731 vs 418 pg/ml in controls; P=0.001). CCNG2 and LYPD6 exhibited significantly increased placental mRNA expression and enhanced intensity of immunohistochemistry staining in placental sections all studied in GD and PE cases. Aberrant expression of mid-gestation specific genes in pregnancy complications at term indicates the importance of the fine-scale tuning of the temporal dynamics of transcription regulation in placenta. Observed significantly elevated plasma STC1 in complicated pregnancies warrants further investigations of its potential as a biomarker. Interestingly, a majority of genes with high expression in mid-gestation placenta have also been implicated in adult complex disease. This observation promotes a recently opened discussion on the role of placenta in developmental programming. 4 samples; this submission is extension of our earlier study (accession GSE22490).</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-37901</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-37901/samples/</item></data></biogps>
